Dr Takayuki Yoshino (National Cancer Center Hospital East, Chiba, Japan) discusses the findings from the phase 3 PARADIGM trial, which was part of a plenary session and selected as one of the top abstracts from the conference. The trial assessed panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment in patients with RAS wild-type metastatic colorectal cancer.
The abstract ‘Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.’ (Abstract number LBA1) was presented at the ASCO annual meeting, 3-7 June 2022.
Questions
- What is the impact of tumour location on prognosis in metastatic colorectal cancer (mCRC)? (00:12-01:30)
- What was already known about the efficacy of initial treatment with panitumumab or bevacizumab plus mFOLFOX6 in the treatment of metastatic colorectal cancer? (01:30-02:58)
Disclosures: Takayuki Yoshino has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.